Skip to content

R01 Renewal Deadlines: NIH Type 2 vs Type 5 Guide

Updated 14 official sources

Quick Answer: An NIH R01 renewal (Type 2) is a competing application due on the R01 renewal, resubmission and revision dates: March 5, July 5 and November 5.

Full answer and how we checked it

With November 5, 2026 past, the next three are March 5, 2027, July 6, 2027 (July 5 is the observed Independence Day holiday) and November 5, 2027, by 5:00 p.m. local time. Plan on the date about 13 months before your project period ends so a resubmission still fits. The parent R21 and R03 notices don't accept renewals at all. Grantsights checked these dates on NIH's standard due dates page (opens in a new tab) on November 8, 2026; other activity codes are in the NIH grant deadlines calendar.

Data note: NIH continuation and renewal requirements were checked July 26, 2026 against current NIH application-type, RPPR, and due-date guidance. Award terms and the current opportunity control the submission route and date.

In this guide

Non-competing continuations (NIH Type 5) continue funding within an approved project period and require the applicable progress-report workflow. Competing renewals (NIH Type 2) request a new project period and undergo peer review. Check the current NIH opportunity, due-date table, award terms, and success-rate data rather than relying on a historic rate.

If you're a PI, grants manager, or program director approaching the end of a grant period, the renewal process is different from a new application, and the mistakes are different too.

The language around "continuation" and "renewal" in federal grants confuses everyone, including experienced investigators. The same word means different things at different agencies, and the processes range from a straightforward progress report to a full-scale competitive application.

Here's what you need to know: at NIH, a "continuation" (Type 5) is basically administrative, while a "renewal" (Type 2) is a second grant application that happens to build on the first one. Understanding which one you're dealing with, and what reviewers and program officers actually look for, determines whether your funding continues or stops.

This guide covers both processes in detail, plus how other agencies like NSF, SAMHSA, and the Department of Education handle renewals.

Non-Competing Continuation (Type 5): The Annual Progress Report

A non-competing continuation is the routine process of receiving the next year's funding within an already-approved multi-year award. If NIH funded your R01 for five years, you don't reapply each year. Instead, you submit a progress report, and the next year's funds are released.

What "Non-Competing" Means

When NIH approves a 5-year R01, they're committing to fund the entire project period, subject to satisfactory progress and available appropriations. The annual continuation isn't a competition. You're not compared against other applicants. You just need to show that you're making reasonable progress and spending the money appropriately.

The Research Performance Progress Report (RPPR)

The RPPR (opens in a new tab) is the standard progress report for NIH grants. It's submitted through eRA Commons and covers:

  1. Accomplishments. What did you do this year? What were the significant results? This section should connect your activities to the specific aims in your funded application.
  2. Products. Publications, datasets, software, patent applications, and other tangible outputs. List everything, even if it's in press or under review.
  3. Participants. Who worked on the project? Any changes in senior/key personnel? Changes in effort?
  4. Impact. How has the project contributed to the field? This can include preliminary findings, methodological advances, or training outcomes.
  5. Changes. Any changes in approach, unobligated balances, or project direction that differ from what was originally proposed?
  6. Special reporting. Human subjects enrollment data, inclusion reporting, and other compliance items.

What Can Go Wrong With a Type 5

Non-competing continuations are almost always approved, but "almost" isn't "always." Your continuation can be delayed or denied if:

  • Unobligated balances or changed needs. The applicable award and agency procedure may require explanation, carryover action, or other review before the next budget period.
  • No progress on the aims. If your RPPR shows little to no progress toward your specific aims with no reasonable explanation, the program officer can place a hold on continuation funding.
  • Compliance failures. Missing required trainings, expired IRB approvals, outstanding audit findings, or delinquent reports on other grants can all hold up your continuation.
  • PI absence. If the PI has left the institution or will be absent for more than 3 months, NIH requires prior approval before continuation funds are released.

Treat the RPPR as a Mini-Proposal

Most investigators write their RPPRs as afterthoughts, listing what they did in the minimum possible words. That's a missed opportunity. Your program officer reads the RPPR, and it shapes their perception of your project. A strong RPPR:

  • Connects results to specific aims explicitly
  • Highlights unexpected findings that opened new directions
  • Acknowledges challenges honestly while showing how you addressed them
  • Includes a clear plan for the next budget period
  • Lists all publications, especially those acknowledging the grant

This matters because the program officer's impression of your progress directly influences how they advocate for your competing renewal when the time comes.


Looking for your next grant?

About once a week, we email a short list of open grant calls with real deadlines from different funders. It lists open calls only.

No spam. Unsubscribe anytime.

Competing Renewal (Type 2): A New Grant Application That Builds on the Old One

A competing renewal is a full application requesting a new project period after the current one ends. It goes through the same peer review process as a new (Type 1) application. The only difference is that you have a track record, and reviewers expect to see it.

Why the Current Award Record Matters

NIH's current success-rate data varies by fiscal year, application type, institute or center, and activity code. A renewal has an established award record, so reviewers can assess productivity, completion of prior work, and the evidence supporting the next project period.

Useful renewal evidence includes:

  • You have preliminary data. Not preliminary data from a pilot study, but actual results from a funded, multi-year project. That's much more convincing.
  • You've demonstrated productivity. Publications, datasets, trained personnel, and established collaborations all signal that you can execute.
  • Reviewers can evaluate execution, not just plans. A renewal application lets reviewers assess whether you delivered on your promises, which reduces the risk perception.
  • Program-officer guidance. A program officer can explain fit, current priorities, and process, but cannot promise funding.

What Reviewers Look For in Renewals

Renewal applications succeed or fail based on a few key factors:

1. Productivity relative to investment. Did the funding produce results proportional to the investment? A 5-year, $1.5 million R01 that produced two mid-tier publications will struggle. The same grant with 8-10 papers, including several in high-impact journals, signals a productive lab.

2. Preliminary data from the current period. The strongest renewal applications use data from the current funding period as the foundation for the next set of aims. This creates a natural narrative: "We proposed X, found Y, and now we're positioned to ask Z."

3. Responsiveness to original aims. Did you stick to the plan, or did you wander? Reviewers understand that science doesn't follow a straight path. But if you proposed three aims and only addressed one, you need to explain why the pivot was scientifically justified.

4. Clear progression. The renewal should feel like the logical next step, not a completely different project. Reviewers want to see that the current funding period built a foundation and the renewal will extend it.

5. Innovation in the renewal aims. A renewal that just proposes "more of the same" won't score well. The new aims should push into territory that the current project made possible but didn't explore.


How to Handle Incomplete Aims in Your Renewal

Not every project goes according to plan. Here's how to handle it.

When You Completed Most But Not All Aims

This is normal and usually not a problem. In the progress report section of your renewal application, explain:

  • What you accomplished on each aim
  • Why the incomplete aim wasn't finished (technical challenges, unexpected findings, personnel changes)
  • What you learned from the attempt
  • How the completed aims inform the renewal's proposed work

Key framing: Position incomplete aims as generating questions that the renewal will answer. "Our attempt to develop Aim 3's assay revealed an unexpected interaction between proteins X and Y, which led us to reformulate Aim 3 as a mechanistic study. This finding directly motivates Aim 1 of the renewal."

When You Pivoted Significantly

If your project took a major turn from the original aims, own it and explain the science. Reviewers respect investigators who follow the data rather than rigidly adhering to a plan that the results don't support.

What you need to show:

  • The original direction was reasonable based on what was known at the time
  • New findings justified the pivot
  • The new direction produced meaningful results
  • The renewal builds on where the science actually is, not where you thought it would be

When Results Were Disappointing

This is the hardest situation. If the project simply didn't produce strong results, you need to be honest about it while showing that you learned something valuable.

  • Explain what the negative results mean for the field
  • Show how the methodological experience positions you for the renewal
  • Propose aims that take a different approach informed by what didn't work
  • If possible, include pilot data from the new approach that shows promise

Reviewers can smell spin. Don't try to make negative results sound like victories. Instead, demonstrate scientific maturity by acknowledging the limitations and showing a clear path forward.


The Progress Report as a Mini-Proposal

Your annual progress report (RPPR for NIH) isn't just an administrative document. It's the foundation for your competing renewal, and it shapes how your program officer views your project. For a detailed walkthrough of progress report writing, see our guide on how to write a grant progress report.

Build Your Renewal Case Over Time

Don't wait until the final year to start thinking about the renewal. Each annual progress report should:

  1. Document achievements clearly. Every publication, dataset, trainee degree, and collaboration goes in the record.
  2. Flag new directions. If your results suggest a promising new avenue, mention it in your progress report. This creates a documented trail showing that the renewal's aims grew naturally from the work.
  3. Address problems early. If an aim isn't working, don't hide it for three years and then explain it in the renewal. Mention it in the progress report and describe your adjusted approach. This shows the program officer (and eventual reviewers) that you're responsive and adaptable.
  4. Track your own metrics. Publications per year, trainees supported, collaborations established, and presentations given. You'll need these numbers for the renewal application.

Publication Strategy for Renewal Success

Publications are the currency of renewal applications. Plan your publication strategy with the renewal timeline in mind:

  • Submit key papers early enough that they're published (not just submitted) before the renewal application deadline
  • Include at least one methods paper if you developed new techniques during the current period
  • Publish negative results if they're informative, as they show productivity and scientific rigor
  • Don't wait to submit the "big paper" if it delays other publications, because multiple solid papers outweigh one outstanding paper that's still in revision

Timeline for Renewal Submission

Timing is everything with renewals because a failed first attempt leaves time for a resubmission only if you planned ahead.

NIH Renewal Timeline

According to NIH's standard due dates (opens in a new tab), R01 renewal, resubmission, and revision applications are due March 5, July 5, and November 5; new R01s are due February 5, June 5, and October 5. The timeline should work backward from your grant's end date:

WhenWhat to Do
18-24 months before endBegin planning renewal aims and identifying gaps in data
12-18 months before endDraft specific aims page, discuss with program officer
9-12 months before endSubmit the renewal application (target one full cycle before end)
If not funded on first trySubmit resubmission (A1) at the next available due date
3-6 months before endIf renewal still pending, prepare for potential gap in funding

Why 9-12 months matters: NIH review takes approximately 9 months from submission to earliest possible funding (submission to review is ~4 months, review to Council is ~2 months, Council to award is ~2-3 months). If your first attempt doesn't succeed, you want time for a resubmission before the current grant ends.

The Funding Gap Problem

If your renewal isn't funded before your current grant ends, you face a gap in funding. Options include:

  • No-cost extension. An extension may be available when authorized by the award and current agency procedure. See our guide on no-cost extensions and confirm the current NIH terms before relying on it to cover a gap.
  • Bridge funding. Many institutions have internal bridge funding programs for PIs awaiting renewal decisions.
  • Administrative supplement. In rare cases, the program officer may support a supplement to cover a short gap, but this isn't common.

NSF Renewal Process

NSF doesn't have a formal "renewal" application type like NIH's Type 2. Instead, you submit a new proposal that references and builds on the prior award.

How NSF Handles Continuations

NSF uses two award types. A standard grant is funded in full at the outset. A continuing grant is funded in annual increments, and under the PAPPG (opens in a new tab) each increment is released subject to satisfactory progress, available funds, and NSF's approval of your annual project report. Either way, NSF has no NIH-style competing renewal: to continue the work after the award ends, you submit a new proposal.

Submitting a Follow-On Proposal

When your NSF grant ends and you want to continue the work, you submit a new proposal through Research.gov (opens in a new tab). In the Project Description, NSF allows (and expects) you to include a section on results from the prior NSF-supported work. According to the PAPPG (opens in a new tab):

  • You can dedicate up to 5 pages of the 15-page Project Description to summarizing prior results
  • This section should include publications, student training, and other outcomes
  • The remaining pages describe the proposed new work

Key Difference From NIH

NSF follow-on proposals don't get the same success rate advantage that NIH renewals enjoy. Your proposal competes on equal footing with all other submissions to that program. Having a prior NSF award helps (it shows you can execute), but there's no formal mechanism that gives renewals preferential treatment.

That said, program officers who know your work and are happy with the results will sometimes suggest specific solicitations or provide informal guidance on how to strengthen a follow-on proposal. Build that relationship by delivering strong results and annual reports.


SAMHSA, Department of Education, and Other Agency Renewals

Not every agency uses the NIH model. Here's how other major federal funders handle renewals.

SAMHSA Competitive Renewals

SAMHSA grants are typically funded for defined project periods (3-5 years) with annual continuation funding. At the end of the project period, SAMHSA sometimes issues a new funding opportunity announcement (FOA) that gives current grantees the chance to compete for continued funding.

These competitive renewals differ from NIH Type 2s because:

  • They're tied to a specific FOA, not submitted under a parent announcement
  • Evaluation criteria often emphasize sustainability and program outcomes rather than innovation
  • Continuation of funding depends heavily on whether the program met its performance measures

Department of Education

ED grants frequently use a "continuation application" process where grantees submit a progress report and budget for the next year. For competitive programs (like those funded under the Education Innovation and Research program), the renewal process is a new competition under a new FOA.

ED reviewers focus heavily on:

  • Whether the project met the goals and objectives in the approved application
  • Evidence of student or participant outcomes
  • Sustainability plans for after federal funding ends
  • Quality of the evaluation data

DOD and DOE

DOD grants are often shorter-term (1-3 years) and usually don't have a renewal mechanism; investigators apply for new awards under new solicitations. DOE's Office of Science is different: under 10 CFR 605 (opens in a new tab), an incumbent recipient can submit a renewal application for further funding of an existing award. Some DOD programs have a phased structure (seed funding followed by larger awards), where Phase 2 functions as a continuation but requires a separate competitive application.


What Program Officers Actually Want to See

Here's what tips the balance on renewal decisions.

The Program Officer's Perspective

Program officers manage portfolios. They want projects that:

  • Produce results that advance the institute's mission
  • Generate publications and other outputs that justify the investment
  • Train the next generation of researchers
  • Don't create administrative headaches (compliance problems, late reports, budget issues)

When a program officer reads your renewal application, they're asking: "Did this project deliver, and will the next period produce even more?" Your application should make that answer obvious.

How to Talk to Your Program Officer About the Renewal

Contact your program officer 12-18 months before the end of your project period. Ask:

  • "Is a renewal appropriate for this project, or should I consider a new application?"
  • "Are there specific areas the institute is prioritizing that my renewal could address?"
  • "Would you recommend any changes to the scope based on what you've seen in my progress reports?"

These conversations don't guarantee funding, but they help you align your renewal with what the institute values. Program officers can't tell you your application will be funded, but they can steer you away from approaches that won't fly.

Red Flags That Sink Renewals

Common red flags include:

  • Low publication output. An R01 that produced one paper in five years will struggle, regardless of the explanation.
  • Budget problems. Large carryover balances or questionable cost transfers suggest poor project management.
  • No new preliminary data. If your renewal aims look like they could have been written without the current grant, reviewers wonder what the funding actually accomplished.
  • Scope creep without justification. The renewal proposes work that has nothing to do with the original project, with no explanation of how the science evolved.
  • Missing trainee outcomes. If you supported postdocs and students, reviewers want to know what happened to them. Did they publish? Get jobs? Win their own grants?


The Publication Timing Problem That Sinks Renewal Applications

The single most common reason a strong research program doesn't get renewed isn't the science. It's the publication timeline. Investigators wait too long to submit key papers, and by the time the renewal application goes in, those papers are still "in revision" or "under review," not published. Reviewers don't count papers that aren't in print. They can't verify the data, the journal's peer review process hasn't validated the work, and study sections have been burned by applicants who list speculative papers as evidence of productivity.

Here's the specific pattern: a renewal application lists the key paper as "in revision," and the study section scores productivity as below expectations because the flagship result isn't verifiable. A resubmission after the paper is accepted can score much better. The science doesn't change between submissions. The paper status does.

Publication strategy matters more relative to the submission date than many PIs appreciate. For NIH R01 renewal deadlines of March 5, July 5, and November 5, you need papers in print, not in revision, by the time the application is assembled, which is typically four to six weeks before the deadline. That means your key paper needs to be accepted by November or December if you're targeting a February 5 deadline. Plan backward from that date. If your paper is likely to need revision rounds at your target journal, either submit it earlier, target a faster-turnaround journal for the flagship paper, or plan your renewal submission for a later cycle. A renewal built around results the PI genuinely has but can't yet show reviewers is at risk. Real results don't help if the timing is wrong.

The RPPR creates a secondary problem that most PIs don't anticipate. During the years before renewal, your annual progress reports build a public record of your productivity. If your RPPR in year three shows "one manuscript in preparation" and your year four RPPR shows the same manuscript still in preparation, your program officer notices. By the time your renewal application arrives, they've already formed a view of your productivity trajectory based on four years of RPPRs. A strong renewal application can partly overcome a weak RPPR record, but it's working against an established narrative. The strongest renewal cases tend to come from investigators whose RPPRs consistently showed forward progress, even in years where results were incomplete. Document your datasets, your conference presentations, your trained personnel. Those outputs count when publications are still in the pipeline.

If your lab trains students and postdocs, pull their outcomes and publications from the project into your most recent RPPR before the renewal goes in. Reviewers read the progress you report, and documented training results support the case that the project used its funding well.

What Agency Renewal Guidelines Don't Tell You About Grant Renewals

Your progress report is your renewal application. Many PIs treat annual progress reports as administrative checklists, but program officers use them to decide whether to recommend your project for continuation. A weak progress report six months before renewal will hurt you more than a strong renewal application.

NIH competing renewals are funded at higher rates than new applications, but only when the progress is there. Grantsights analysis of NIH Data Book table 206 shows R01 renewals were funded at 22.8% in FY2025 (661 of 2,898), against 9.9% for new R01s (3,405 of 34,491). Reviewers judge a renewal against your original promises, so if your aims didn't produce significant results, a new R01 with revised aims can still be the better route.

No-cost extensions aren't free. Taking a no-cost extension signals to the agency that your project is behind schedule. One NCE is normal. Two NCEs will prompt questions from your program officer about whether the project is viable. Avoid using NCEs as a default strategy for spending down remaining funds.

How Grantsights Checked This Guide

Grantsights data and our analysis reviewed current NIH continuation and renewal sources in June 2026 and compared them with renewal pages that rank for Type 2 and Type 5 intent. Where official sources stop: official pages define application types, but applicants need an evidence test for whether to renew, resubmit, or restart as new. According to NIH, annual, final, and interim RPPRs have separate uses, and according to NIH, Type 2 renewals must be developed as full competing applications.

Official source checkedCurrent rule or signalApplicant decision
NIH RPPR (opens in a new tab)According to NIH, annual, final, and interim RPPRs serve different purposes, and Interim RPPR is used when submitting a renewal Type 2 application.Treat the RPPR as the renewal record, not just an annual report.
NIH types of applications (opens in a new tab)According to NIH, Type 2 renewals compete for funding and must be developed as fully as though applying for the first time.Do not submit a thin update. Build a full application with productivity evidence.
NIH Grants Policy Statement application types (opens in a new tab)According to NIH, Type 5 is a non-competing continuation progress report and Type 2 is a renewal.Separate administrative continuation work from competitive strategy.
NIH standard due dates (opens in a new tab)According to NIH, new, renewal, resubmission, and revision applications can have different standard due dates.Pick the due date by application type, not by habit.
NIH RPPR instruction guide (opens in a new tab)According to NIH, Final RPPR normally applies if you do not apply for a competing renewal, while Interim RPPR applies when you do.Decide renewal intent before the closeout clock creates rework.

Bad fit check: skip the renewal route if your current award has weak outputs, unresolved compliance issues, no clear next question, or aims that read like more of the same. A new application may be a better route when continuity is not the main strength.

For example, a PI with strong publications can still write a renewal draft that repeats the old aims. The stronger route is a Type 2 application built around what the funded period revealed, with the RPPR record, publications, and new preliminary data doing the credibility work.

Use this page with our progress report guide, NIH specific aims guide, NIH study section guide, grant reporting guide, and federal grant systems guide. For active renewal-related opportunities, use the grant search hub and compare support options on Grantsights pricing.

Sources

  1. NIH Types of Applications (opens in a new tab) - Official definitions of Type 1 through Type 9 application types.
  2. NIH Extramural Nexus: R01 Type 2 Characteristics and Outcomes (opens in a new tab) - NIH data on competing renewal success rates.
  3. NIAID: Apply for a Renewal (opens in a new tab) - NIAID guidance on the competing renewal process.
  4. NIMH: Competing Continuation (Renewal) Awards (opens in a new tab) - NIMH-specific renewal policies.
  5. NSF PAPPG Chapter II: Proposal Preparation (opens in a new tab) - NSF requirements for proposals that build on prior awards.
  6. NIH RePORT: Success Rates (opens in a new tab) - Official NIH success rate data by application type and fiscal year.

Frequently Asked Questions

What's the difference between a non-competing continuation and a competing renewal?

A non-competing continuation (Type 5 at NIH) continues funding within an already-approved project period. You submit a progress report, not a full application, and you don't compete against other applicants. A competing renewal (Type 2 at NIH) requests a new project period after the current one ends. It's a full application that goes through peer review and competes with all other applications. The key difference: Type 5 is largely administrative, while Type 2 requires the same effort as a new grant application.

What is the success rate for NIH competing renewal applications?

NIH publishes success-rate data by fiscal year, activity code, and application type. Do not use a historic Type 2 percentage to predict an individual renewal. Review the current NIH success-rate tables, the institute or center's funding information, the opportunity, and the strength of the renewal's productivity and preliminary-data record.

When should I submit my competing renewal application?

For NIH, submit your Type 2 renewal application one full funding cycle before your current project period ends. That typically means 9-12 months before the end date. NIH standard due dates for R01 renewals are March 5, July 5, and November 5 (new R01s use February 5, June 5, and October 5). If your R01 ends March 31, the July 5 renewal date of the prior year leads to an earliest start in April, about 9 months later, while the March 5 date gives about 13 months and room for a resubmission. Earlier is better because it gives you time for a resubmission if the first attempt isn't funded.

What if I didn't achieve all of my original specific aims?

Not completing every aim isn't automatically disqualifying, but you need to address it directly. Explain what you learned from the aims you did complete, why the incomplete aims didn't work (was the methodology flawed, or did unexpected findings redirect the work?), and how those results inform the proposed renewal. Reviewers want to see scientific judgment, not just execution of a checklist. If you pivoted to a more productive direction based on early results, that can actually strengthen your renewal. What hurts is having nothing to show and no explanation.

How does the NSF renewal process differ from NIH?

NSF doesn't have a formal 'renewal' mechanism equivalent to NIH's Type 2. Instead, you submit a new proposal that references and builds on the prior award. In the Project Description, you include a section (up to 5 pages for standard grants) summarizing the results of the prior NSF-supported work, including publications and outcomes. This functionally serves as a renewal application, but it goes through the same review process as any new proposal. The success rate advantage that NIH renewals enjoy doesn't apply at NSF in the same way.

Last updated October 9, 2026. Corrected October 8, 2026: what changed. Published by Grantsights from public sources. See our editorial policy, how we build and check guides, corrections and how we make money.